The ball now is in Boston Scientific Corp.’s court in the battle to woo cardiovascular device maker Guidant Corp. away from Johnson & Johnson, which sweetened its bid to acquire Guidant, analysts said on Thursday.
*For more on this story,
read the full Reuters article.
